Latest Regulatory Filings News

Immutep Limited has confirmed 30 mg as the optimal biological dose for its immunotherapy efti, following FDA approval of Project Optimus requirements. This milestone paves the way for the US launch of its pivotal Phase III lung cancer trial.

NSX Limited shareholders have overwhelmingly approved a scheme of arrangement for acquisition by a CNSX Markets-related entity, setting the stage for a significant market transition pending court approval.

NexGen Energy Ltd. has launched a significant dual equity financing, successfully upsizing its Australian offering and targeting combined proceeds exceeding C$1 billion. This move underscores the company's strategic capital expansion across North American and Australian markets.

The Royal Court of Jersey has approved Harmony Gold’s acquisition of MAC Copper, setting the stage for MAC’s trading suspension and delisting from ASX and NYSE.

Vonex Limited’s shares will be suspended from ASX trading following court approval of its acquisition by Maxo Telecommunications, marking a pivotal moment for the telecom services company.

Immuron Limited has taken a significant step forward by submitting an Investigational New Drug application to the FDA for IMM-529, targeting Clostridioides difficile infection. The company aims to start Phase 2 trials in early 2026, addressing a critical unmet need in infectious disease treatment.

One Click Group has locked in $1.25 million through a share placement, bringing Thorney Investment Group on board as a major shareholder and accelerating its Cash Advance product launch.

Predictive Discovery Limited and Robex Resources Inc. have agreed to merge, creating a mid-tier gold producer in West Africa with combined output expected to exceed 400,000 ounces annually by 2029.

Dimerix Limited’s lead drug candidate DMX-200 has been granted Orphan Drug Designation in Japan for treating Focal Segmental Glomerulosclerosis (FSGS), enhancing its regulatory and commercial prospects in a key market.

Imagion Biosystems has completed the second tranche of its $3.5 million placement, raising $2.85 million to advance its proprietary MagSense® imaging technology targeting breast, prostate, and ovarian cancers.

ReNerve Ltd is rapidly advancing its nerve repair product portfolio, with four ranges expected on the market by the end of 2025 and expanding global distribution. Clinical studies highlight significant patient benefits, supporting the company’s growth in a booming biomaterials market.

Vonex Limited shareholders have overwhelmingly approved Maxo Telecommunications’ acquisition scheme, setting the stage for a court decision that could delist Vonex from the ASX.